

(19) World Intellectual Property
Organization
International Bureau



554314

(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/095031 A1

(51) International Patent Classification⁷: **G01N 33/68**

(21) International Application Number:
PCT/EP2003/011413

(22) International Filing Date: 15 October 2003 (15.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/464,888 24 April 2003 (24.04.2003) US

(71) Applicant (*for all designated States except US*): **UNIVERSITÄT ZÜRICH [CH/CH]**; Rämistrasse 71, CH-8006 Zürich (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOCK, Christoph**

[DE/CH]; Rietstrasse 43, CH-8703 Erlenbach (CH). **KONIETZKO, Uwe [DE/CH]**; Witellikerstrasse 22/263, CH-8008 Zürich (CH). **NITSCH, Roger [DE/CH]**; Guggerstr. 19, CH-8702 Zollikon (CH).


(74) Agents: **MEYERS, Hans-Wilhelm et al.**; von Kreisler Selting Werner, P.O. Box 10 22 41, 50462 Cologne (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: **METHOD OF MONITORING IMMUNOTHERAPY**



(57) Abstract: The present invention relates to a method of monitoring an immunotherapy against amyloidosis and other diseases characterized by the deposition of abnormal protein aggregates. More specifically, it relates to a method of evaluating an immunotherapy against Alzheimer's disease, based on a novel assay that is characterized by scoring immunoreactivity levels of patient sera in amyloid plaque containing samples. The assay possesses highly predictive properties in relation to the clinical outcome of such an immunotherapy, in contrast to previously used, conventional ELISA assays. Therefore, the novel assay is useful for the evaluation of the efficacy of an immunotherapy in a patient suffering from amyloidosis, particularly Alzheimer's disease.

WO 2004/095031 A1



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*